Trial Profile
A phase I/II study of nab-paclitaxel (Abraxane) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Folinic acid; Gemcitabine; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms SEQUENCE
- 07 Jun 2022 Primary endpoint has been met (Phase II: Overall survival al 12 months after treatment initiation) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results (n=157) reporting safety profile and clinical activity from phase II portion of this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 11 Aug 2021 Status changed from active, no longer recruiting to completed.